“Our common objective is to develop, procedure and provide innovative treatment options for all patients, who are still waiting for hope and help in the treatment of their orphan diseases. We feel more like partner than a vendor for both scientific community and patient organizations."
"It is our intention to contribute continuously to improvement of the rare disease treatment standards. Despite the organization growth we want to remain the company that is enthusiastic, pioneering, professional and empathetic, keeping the company philosophy that the patient is on the first place!"
AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialisation of drugs for more than 20 years already.
Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Czech health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases.
Czech Republic occupies a special position among many countries where AOP Orphan is represented. In this market, the company began its development in 2003. AOP Orphan in Czech Republic is comprised of experienced and qualified team members in Marketing & Sales, and Medical for all four therapeutic divisions.